Global Neurological Disorder Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Neurological Disorder Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
Due to the COVID-19 pandemic, the global Neurological Disorder Drugs market size was US$ 19270 million in 2022 and is forecast to a readjusted size of US$ 24800 million by 2034 with a CAGR of 3.6% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Antipsychotic accounting for % of the Neurological Disorder Drugs global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Hospital segment is altered to an % CAGR throughout this forecast period.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Neurological Disorder Drugs market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Neurological Disorder Drugs market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Neurological Disorder Drugs market. Readers of the report can become informed about current and future trends of the global Neurological Disorder Drugs market and how they will impact market growth during the forecast period.
Novartis
GlaxoSmithKline
Merck & Co.
Bayer
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
Segment by Type
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Hospital
Clinic
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Neurological Disorder Drugs in global and regional level.
Chapter 3Detailed analysis of Neurological Disorder Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurological Disorder Drugs revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Due to the COVID-19 pandemic, the global Neurological Disorder Drugs market size was US$ 19270 million in 2022 and is forecast to a readjusted size of US$ 24800 million by 2034 with a CAGR of 3.6% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Antipsychotic accounting for % of the Neurological Disorder Drugs global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Hospital segment is altered to an % CAGR throughout this forecast period.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Neurological Disorder Drugs market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Neurological Disorder Drugs market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Neurological Disorder Drugs market. Readers of the report can become informed about current and future trends of the global Neurological Disorder Drugs market and how they will impact market growth during the forecast period.
By Company
Novartis
GlaxoSmithKline
Merck & Co.
Bayer
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
Segment by Type
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Segment by Application
Hospital
Clinic
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Neurological Disorder Drugs in global and regional level.
Chapter 3Detailed analysis of Neurological Disorder Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurological Disorder Drugs revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices